top of page


DASH is a privately held, specialty pharmaceutical company.  The company markets, sells, and distributes generic pharmaceutical products, packaged in the “DASH” label, to the US marketplace.  


We continually evaluate and identify generic product opportunities, across multiple dosage forms and therapeutic categories. 


Through partnerships with quality pharmaceutical manufacturers around the world, we co-develop and license products for distribution in the US market.


CEO and Co-Founder
  • LinkedIn

Nick Dimaio

President and Co-Founder
  • LinkedIn
  • An experienced senior executive in the life sciences and financial services industries and serial entrepreneur, with a proven track record in business management, business development, product and operational management

  • Co-Founder of Rising Pharmaceuticals, a leading US distributor of specialty generic pharmaceutical products

  • 15+ years co-managed Rising’s business and focused on pipeline strategy and BD

  • Built and maintains an extensive base of formulation and manufacturing partners throughout the US, Europe and Asia

  • Following the successful sale of Rising to the Aceto Corporation in 2010, Dave helped transform Aceto from a traditional chemical distribution company into a fast-growing human health/pharmaceutical company.

  • 25+ years pharmaceutical industry experience with leading branded and generic manufacturers

  • Positions of increasing responsibility in the following areas: field sales, key account management, national sales analysis, product management, marketing, sales and marketing management

  • Co-founder of Karalex Pharma, LLC a privately held generic sales, marketing , and distribution company

  • Executive Vice President, Sales and Marketing for Par Pharmaceuticals. Managed a pharmaceutical sales and marketing team that grew sales from $80 million to $500 million over an 8-year period.

  • Served as Director of Marketing for Apothecon, the generic division of Bristol Myers Squibb. Responsible for marketing a $500 million line of generic Rx products.

Julie Trendowicz

EVP and Co-Founder
  • LinkedIn
  • 25+ years pharmaceutical industry experience with many of the leading generic manufacturers

  • management positions in sales and in operations planning

  • Co-founder of Karalex Pharma, LLC a privately held generic sales, marketing, and distribution company

  • Vice President of Sales for Par Pharmaceuticals. Built and directed a sales team that grew annual revenue from $80 million to over $500 million over an 8-year period

  • VP, Sales & Marketing for Copley Pharmaceuticals. Responsible for growing business from a base of $2.0 million in sales to a publicly traded organization with sales of over $125 million over a 13-year period.

Our Team
bottom of page